 |
인쇄하기
취소
|
Kwangdong to introduce new rheumatoid arthritis treatment
Kwangdong Pharm has announced that it has signed an exclusive license agreement with Israel based Can-Fite BioPharma Ltd. to develop and commercialize the drug CF101 for the treatment of rheumatoid arthritis in Korea.
kwangdong plans to launch CF101 in 2013 after completion of local clinical trials and market authorization.
"We are most honored that such a reputable company has decided t...
kwangdong plans to launch CF101 in 2013 after completion of local clinical trials and market authorization.
"We are most honored that such a reputable company has decided t...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.